​Voluntary withdrawal of Blenrep® from U.S. market

January 13, 2023

​On November 22, 2022, GlaxoSmithKline decided to voluntarily withdraw the Biologic License Application (BLA) for Blenrep® (belantamab mafodotin-blmf).  

How does this affect our members?

GlaxoSmithKline will send letters to providers who prescribe Blenrep to notify them about this decision. These letters will include information about the compassionate use of Blenrep for individuals who are currently receiving the drug. Independence Blue Cross and Independence Administrators (collectively, Independence) will continue to cover Blenrep for these members. New requests for Blenrep will not be covered by Independence.

For more information

The complete statement on the U.S. market withdrawal of Blenrep, including details about the compassionate use program, is available on the GlaxoSmithKline website. ​